FDA, vaccine
Digest more
7hon MSNOpinion
When the Food and Drug Administration said last month that Dr. Richard Pazdur, a long-tenured, widely-respected FDA leader, would lead the agency’s drug review division, it seemed a sign that things were finally getting back to normal.
The US Food and Drug Administration’s longtime oncology chief has filed to retire from the agency just weeks after he was chosen to lead the FDA’s drug division, according to four people familiar with his decision.